Professor, Pathology, University of Texas Southwestern Medical Center, Southwestern Medical School
Oncology
Dr. Adi F. Gazdar, MD
Adi F. Gazdar, MD is an expert in the field of Oncology. Doctor Adi F. Gazdar, MD is also published. He has 101 publications published. The lastest publication: "Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?'
Publications
- From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.
- Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.
- High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma.
- The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.
- Molecular portraits of epithelial, mesenchymal and hybrid states in lung adenocarcinoma and their relevance to survival.
- Genetic mutation of p53 and suppression of the miR-17~92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D signaling.
- ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
- Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.
- A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes expanding the repertoire of potential immunotherapeutic targets.
- Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations.
- EGFR mutations in lung cancer: different frequencies for different folks.
- YEATS4 Is a Novel Oncogene Amplified in Non-Small Cell Lung Cancer That Regulates the p53 Pathway.
- Identification of Breast Cancer DNA Methylation Markers Optimized for Fine-Needle Aspiration Samples.
- Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.
- CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer.
- Precision Medicine for Cancer Patients: Lessons Learned and the Path Forward.
- Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/Euro...
- Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/Europ...
- SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.
- miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers.
- Potential Application of Non-small Cell Lung Cancer-associated Autoantibodies to Early Cancer Diagnosis.
- SMAC Mimetic (JP1201) Sensitizes Non-Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-?-Independent Manner.
- Predictive and Prognostic Factors for Non-Small Cell Lung Cancer--Potholes in the Road to the Promised Land.
- Transient but Not Stable ZEB1 Knockdown Dramatically Inhibits Growth of Malignant Pleural Mesothelioma Cells.
- Methylation profiling of lung cancer: a decade of progress.
- TRAF6 is an amplified oncogene bridging the RAS and NF-?B pathways in human lung cancer.
- Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts.
- Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
- Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study.
- Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
- Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer.
- Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
- Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells.
- Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer: To Test or Not to Test?
- Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis.
- Malignant mesothelioma: Facts, myths and hypotheses.
- Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
- Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.
- Lung cancer cell lines as tools for biomedical discovery and research.
- Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
- A risky business--identifying susceptibility loci for lung cancer.
- Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
- Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
- Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harbori...
- Personalized medicine and inhibition of EGFR signaling in lung cancer.
- Color fluorescence ratio for detection of bronchial dysplasia and carcinoma in situ.
- Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
- MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
- PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
- Multifocal lung cancers--clonality vs field cancerization and does it matter?
- Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
- Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
- Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
- Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
- Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene.
- PIK3CA mutations and copy number gains in human lung cancers.
- Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.
- DNA methylation in lung cancer.
- Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.
- Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay.
- Application of Multidimensional Selective Item Response Regression Model for Studying Multiple Gene Methylation in SV40 Oncogenic Pathways.
- Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
- Evaluation of candidate methylation markers to detect cervical neoplasia.
- Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
- The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.
- Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung.
- Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently i...
- Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers.
- Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.
- A translational view of the molecular pathogenesis of lung cancer.
- Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
- DNA repair and survival in lung cancer--the two faces of Janus.
- Lung cancer, smoke exposure, and sex.
- A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
- The consensus coding sequences of human breast and colorectal cancers.
- Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
- HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
- Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
- Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
- High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
- Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic featu...
- Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers.
- Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial...
- Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia.
- Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.
- Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
- Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines.
- Rapid screening for EGFR mutations: pros and cons.
- Lung cancer preneoplasia.
- Inhibition of EGFR signaling: all mutations are not created equal.
- Genomic alterations in cultured human embryonic stem cells.
- Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.
- Novel real-time PCR assay using a universal molecular marker for diagnosis of hematologic cancers.
- EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
- Gefitinib versus cetuximab in lung cancer: round one.
- Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Doctors Specialties
- Oncology
Accepted Insurances
Hospital
-
University of Texas Southwestern Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Charles L. Cowey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Minna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ashwani K. Agarwal, MB
This Doctor is OpenDoctor Recommended.
|